ISSN 1662-4009 (online)

ey0020.8-13 | New Mechanisms | ESPEYB20

8.13. Low-dose IL-2 reduces IL-21(+) T cell frequency and induces anti-inflammatory gene expression in type 1 diabetes

JY Zhang , F Hamey , D Trzupek , M Mickunas , M Lee , L Godfrey , JHM Yang , ML Pekalski , J Kennet , F Waldron-Lynch , ML Evans , TIM Tree , LS Wicker , JA Todd , RC Ferreira

Brief summary: This study used high-resolution single-cell multiomics and flow cytometry on blood samples from patients with type 1 diabetes (T1D) to examine the effects of low-dose recombinant IL-2 (iLD-IL-2). Administration of iLD-IL-2 expanded thymic-derived FOXP3+HELIOS+ Tregs and CD56bright NK cells, reduced frequency of IL-21-producing CD4+T cells, and induced long-lived anti-inflammatory transcriptional changes in all T and NK...

ey0020.13-5 | Section | ESPEYB20

13.5. Intermittently scanned continuous glucose monitoring for type 1 diabetes

L Leelarathna , ML Evans , S Neupane , G Rayman , S Lumley , I Cranston , P Narendran , K Barnard-Kelly , CJ Sutton , RA Elliott , VP Taxiarchi , G Gkountouras , M Burns , W Mubita , N Kanumilli , M Camm , H Thabit , EG Wilmot , FLASH-UK Trial Study Group

In Brief: This multicenter, randomised controlled trial in 156 adults (mean age 44 years) with type 1 diabetes (T1D) showed benefits of intermittently scanned continuous glucose monitoring (CGM) (intervention) compared to usual monitoring of blood glucose levels by fingerprick testing on: lower HbA1c (−0.5%; P<0.001), 130 minutes/day longer duration of ‘in target’ glucose levels, and 43 minutes/day shorter time spent with hypoglycaemic blood glucos...